Payment overview · 2025
General Payments
$895.70
29 reported records · 16 companies
Healthcare provider profile · identity verified
Nisarfathima Kazimuddin, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Critical Care Medicine · BOWLING GREEN, KY · NPI 1124028006
Verified facts
What the public records show
CMS Open Payments records show Nisarfathima Kazimuddin, MD received $895.70 in general payments during 2025 across 29 reported records.
Insmed, Inc. accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Xyrem.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Trelegy Ellipta by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYREM as an associated drug or biological on 613 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xyrem by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insmed, Inc. | Unresolved — no canonical attribution shown | $193.37 | 21.6% | 9 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $150.00 | 16.8% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $99.99 | 11.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $72.85 | 8.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $70.04 | 7.8% | 3 | 2025 |
| La Jolla Pharmaceutical Company | Unresolved — no canonical attribution shown | $48.00 | 5.4% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $39.07 | 4.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $38.74 | 4.3% | 2 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $37.00 | 4.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $32.99 | 3.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.10 | 2.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.58 | 2.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.85 | 2.3% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $16.52 | 1.8% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.98 | 1.8% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $13.62 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $645.71 | 27 |
| Consulting Fee | $150.00 | 1 |
| Education | $99.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $193.37 | 9 | 2025 |
Source payment records
|
|||||
| XYREM Normalized: xyrem |
Drug | JAZZ PHARMACEUTICALS INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $72.85 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $70.04 | 3 | 2025 |
Source payment records
|
|||||
| GIAPREZA Normalized: giapreza |
Drug | La Jolla Pharmaceutical Company | $48.00 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $39.07 | 1 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $37.00 | 2 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $32.99 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $26.83 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $22.58 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| CDS - MCT/CEM Monitoring Normalized: cds mct cem monitoring |
Device | Boston Scientific Corporation | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| Kcentra Normalized: kcentra |
Biological | CSL Behring | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| XYREM xyrem |
2025 | Xyrem | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
163 | 35 |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | XYREM open payments reported associated product |
CMS Open Payments — General Payments 613 supporting records · 589 recipient NPIs · example record 1234298066 |
Xyrem · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 188 | 54 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 163 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | suppressed |
| Gabapentin | Gabapentin | 55 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 38 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 37 | 17 |
| Doxepin Hcl | Doxepin Hcl | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | 16 |
| Furosemide | Furosemide | 29 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | 11 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 24 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 22 | suppressed |
| Bumetanide | Bumetanide | 20 | 11 |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 15 |
| Prednisone | Prednisone | 15 | 13 |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Xyrem | Sodium Oxybate | 12 | suppressed |
| Dupixent Pen | Dupilumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $895.70 · 29 records | Insmed, Inc. | AMPLATZER AMULET, Arikayce, BodyGuardian, Brinsupri, CDS - MCT/CEM Monitoring, GIAPREZA, Hillrom - Carnation Ambulatory Monitor, INSPIRE, Kcentra, Kerendia, LUMRYZ, NUCALA, PURIFIED CORTROPHIN GEL, WINREVAIR, XYREM, XYWAV, YUPELRI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Xyrem play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error